The 2026 ASCO Annual Meeting marks a critical inflection point for the pharmaceutical industry. Breakthrough clinical data, accelerating innovation in antibody-drug conjugates (ADCs), and increasingly competitive therapeutic classes are reshaping how companies compete and how investors evaluate value.
The pre-conference report explores the most important pipeline developments, commercial signals, and competitive dynamics emerging ahead of ASCO 2026, providing a clear view of where the oncology market is headed next.
